Nonhormonal treatment guides
Understand the approach.
Keep the details.
Read about treatment families, newer medicines, product-specific safety and the goals to bring to a menopause discussion.
Guide
Non-estrogen medication for hot flashes: understand the treatment families
Separate antidepressant medicines, neurokinin-targeted treatments, other prescriptions and evidence-based non-drug support without ranking them for an individual.
Guide
Fezolinetant and liver monitoring: understand the responsibility behind the tests
What Veozah's current boxed warning adds to a hot-flash treatment discussion, and why a laboratory order needs a clear review and response process.
Guide
Lynkuet vs Veozah: a guide to comparing the evidence
Compare the questions each product raises, read the trial limits and prepare for a discussion about treatment and follow-up.
Guide
Prepare a nonhormonal menopause visit around the result that matters to you
Bring symptom priorities, previous treatment experience and practical follow-up questions without trying to choose a prescription from an online checklist.
Guide
Paroxetine’s Menopause Trials: Reading Hot-Flash and Sleep Outcomes Together
Two placebo-controlled trials support a specific hot-flash benefit, while a secondary analysis found modest improvements in symptom-attributed awakenings and sleep duration. Those findings answer a different question from fezolinetant’s research program.
Guide
SKYLIGHT 1: Fezolinetant’s Symptom Effects and Evolving Liver-Safety Evidence
The 527-participant trial established a placebo-adjusted symptom benefit over 12 weeks. Its findings answer a different question from paroxetine’s sleep analyses—and must now be read alongside VEOZAH’s boxed liver warning.